Signaling lymphocytic activation molecule family-1 (CD150) expression as a prognostic indicator in patients with chronic lymphocytic leukemia

Abstract

Introduction Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy characterized by the accumulation of mature monoclonal CD5-positive B-lymphocytes in the peripheral blood, bone marrow, and secondary lymphoid tissues. It is characterized by remarkable clinical variability. CD150 is a multifunctional type I transmembrane glycoprotein; it has been suggested that CD150 expression modulates CLL response to chemokines and regulates autophagy. Aim The aim of this study was to determine the expression of CD150 in patients with CLL and its relation to the other well-established prognostic markers and also to determine its impact on patient survival. Patients and methods This case–control study was performed on 50 newly diagnosed CLL patients and 50 apparently healthy individuals as a control group. CD150 expression was measured by flow cytometry. Results This study has shown that CD150 expression was decreased in CLL patients compared with the control group, with great heterogeneity between CLL patients. There were negative correlations between CD49d, CD38, ZAP-70 expression, clinical staging of CLL patients, and CD150 expression, whereas there were positive correlation between hemoglobin level, platelets count, and CD150 expression. Patients with CD150 expression less than or equal to 6% of CD19-positive B-lymphocytes have shorter progression-free survival and overall survival and needed to start treatment early. Conclusion CD150 can be a useful tool in identifying B-CLL patient’s risk.